Madrigal Pharmaceuticals Inc
MDGL
Company Profile
Business description
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Contact
200 Barr Harbor Drive
Suite 200, Four Tower Bridge
West ConshohockenPA19428
USAT: +1 267 824-2827
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
915
Stocks News & Analysis
stocks
ASX payments utility looks overvalued
Australia’s invisible payments utility earns narrow moat yet valuation looks lofty.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,840.00 | 54.60 | -0.61% |
| CAC 40 | 7,769.21 | 95.86 | -1.22% |
| DAX 40 | 25,104.36 | 344.83 | -1.35% |
| Dow JONES (US) | 51,179.87 | 341.41 | -0.66% |
| FTSE 100 | 10,458.50 | 83.19 | -0.79% |
| HKSE | 24,047.13 | 83.37 | -0.35% |
| NASDAQ | 27,538.69 | 61.20 | -0.22% |
| Nikkei 225 | 69,373.40 | 662.31 | -0.95% |
| NZX 50 Index | 13,651.88 | 32.16 | -0.24% |
| S&P 500 | 7,801.77 | 17.16 | -0.22% |
| S&P/ASX 200 | 8,677.30 | 50.40 | -0.58% |
| SSE Composite Index | 3,833.59 | 8.60 | -0.22% |